Principal Scientist / February, 2022 — Present

Was hired to maximize treatment value through patient-centered outcomes • Support executive team to enhance product value proposition through robust Value & Access strategy • Champion excellence in HEOR and PRO/COA strategy implementation through effective in-house project management and strategic oversight • Maximize the value propositions of medical products through the development of HEOR and PRO/COA strategy focused on multiple stakeholders (patients, caregivers, regulators, HTA and payer agencies, and policymakers) • Persuasively communicated the unique value of products to multiple stakeholders, securing their support and partnership • Enable excellence and compliance in the planning, execution, and publication of HEOR and PRO/COA research by optimizing scientific planning, oversight, and publication approval processes

Head of Value & Access / January, 2023 — December, 2023

Was hired to build V&A capacity and shape the product value proposition • Addressed and resolved pivotal issues to refine business strategies and optimize decision-making in development programs • Crafted and articulated a compelling product value story, tailored to optimize value from the payer perspective • Formulated a robust Value & Access (V&A) strategy, concentrating on current and future indications to enhance market positioning • Established strategic relationships with key payer decision-makers, fostering avenues for impactful collaborations • Facilitated a standout market debut for a company emerging from stealth mode through strategic planning and execution of key publications • Established and maintained company-level standards of excellence and compliance in HEOR and PRO/COA research planning, execution, and publication, through streamlined scientific planning, meticulous oversight, and robust publication approval processes

Director, PRO and COA Center of Excellence / March, 2020 — February, 2022

Was hired to ensure excellence in COA strategy, execution, analyses, and publications • Enabled successful PRO discussions with regulatory agencies (FDA, EMA) by contributing to briefing documents and participating in meetings with the FDA • Drove excellence in patient-focused drug development by developing training on the value of PRO/COA for multiple stakeholders and best practices in PRO/COA strategy and research • Ensured success of critical (high-priority and high-visibility) projects by advising therapeutic-area HEOR colleagues on PRO strategy during launches, protocol design, COA analyses, and regulatory communications • Enabled excellence and compliance in the planning, execution, and publication of PRO/COA research by optimizing scientific planning, oversight, and publication approval processes • Maximized the value of Gilead products by optimizing PRO/COA for HTA and payer decisions

Director, Health Economics and Outcomes Research / September, 2017 — February, 2020

Was hired to create a comprehensive research agenda to demonstrate the value of a multi-indication product via real-world evidence and clinical outcome assessment • Led, developed, and executed HEOR strategy supporting a product launch • Communicated the value Gilead products by leading 25+ publications • Gilead Sciences (continued) • Enabled successful publications of PRO and COA in clinical trial result in oncology, inflammation, liver disease • Strengthened clinical programs by informing clinical trial design, statistical analysis plans, and best practices in PRO and COA methodology • Elevated Gilead recognition in the clinical and scientific communities by cultivating and managing relationships with clinical experts and key opinion leaders (KOLs)

Senior Health Economist / February, 2014 — August, 2017

Was hired to lead HEOR activities (economic modeling, real-world evidence, COA research) for 2 sequential launches • Ensured close cross-functional integration of HEOR strategy through collaborative development and execution of HEOR strategic plans • Enabled two successful launches of two line-extensions through RWE, economic modeling, and PRO research • Enabled the successful assessment of PRO in Genentech Phase 4 and observational studies by developing PRO strategy and informing endpoint • Facilitated patient centricity in clinical practice by developing an iOS app (MyHivesDiary) to collect symptoms of chronic idiopathic urticaria (CIU) in daily life • Expanded the value of Xolair by developing publication strategy and leading 50+ peer-reviewed publications (receiving 4 publication awards)

Senior Manager, Health Economics and Outcomes Research / March, 2011 — December, 2013

Was hired to support a product launch in the EU, set up and execute a comprehensive research agenda, and communicate the product value through publications • Ensured a successful launch of a MedImmune product by executing and publishing HEOR research (RWE, economic modeling, value dossier) • Advised expansion of value proposition in oncology by outlining the highest unmet need in patients through early-phase economic modeling • Informed national and local policies on pediatric vaccination in the US and UK through economic models demonstrating that vaccination of school-age children protects the elderly from influenza morbidity and mortality

Research Scientist / July, 2008 — February, 2011

Was hired to support a portfolio of multiple indications to ensure comprehensive value proposition, HEOR strategy • Supported a successful launch of an acquired (short-notice) product through the leadership developing PRO strategy and executing qualitative research to support the PRO instrument design • Ensured breadth and strength of treatment value by leading cross-functional work on the development of value-proposition documents for products in men’s health and musculoskeletal health • Supported the expansion of the treatment value proposition by developing PRO strategy for clinical trials • Maximized the value of treatments by advising clinical trial design and instrument development; represented PRO expertise at the FDA meetings